Loading
RT
RAPT Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Robbins Wendye, was filed 15 Mar 2023.
RAPT Therapeutics, Inc.: what insiders have been doing
RAPT Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 20 October 2026, brought 15 filings signed by 9 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
With 15 filings in twelve months, the company is quieter than the median of 22 filings across the 5,453 companies we follow on the same exchange. The full history, which starts in 2020, counts 27 purchases against 68 sales.
There has been no open-market purchase by an insider of RAPT Therapeutics, Inc. for at least a year. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
156
Thresholds
n/a
Buy Volume
€13M
27 ops. · all time
Sell Volume
€57M
68 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
Net income-US$111.8M
Last declaration on 5 March 2026
Declarations156 total
3,304 sharesCommon StockSEC:0001337831-26-000001:0
4,956 sharesCommon StockSEC:0001693564-26-000003:0
64,102 sharesCommon StockSEC:0001646110-26-000001:0
4,956 sharesCommon StockSEC:0001643875-26-000006:0
4,956 sharesCommon StockSEC:0001782274-26-000003:0
4,956 sharesCommon StockSEC:0001733915-26-000003:0
4,648 sharesCommon StockSEC:0001635616-26-000001:0
4,956 sharesCommon StockSEC:0001270774-26-000003:0
4,956 sharesCommon StockSEC:0001261974-26-000003:0
4,956 shares0Common StockSEC:0001782274-26-000002:0
4,956 shares0Common StockSEC:0001733915-26-000002:0
4,956 shares0Common StockSEC:0001693564-26-000002:0
4,956 shares0Common StockSEC:0001643875-26-000002:0
4,956 shares0Common StockSEC:0001270774-26-000002:0
4,956 shares0Common StockSEC:0001261974-26-000002:0
1,352,008 sharesCommon StockSEC:0000950170-24-139754:0
1,352,008 sharesCommon StockSEC:0000950170-24-139755:0
898 shares@ US$22.785.8% of flowCommon StockSEC:0001415889-24-000817:0
8,000 shares@ US$6.1813.8% of flowCommon StockSEC:0001593968-24-000003:0
2,500 shares@ US$21.682.5% of flowCommon StockSEC:0001593968-23-001523:0
1,500 shares@ US$13.720.9% of flowCommon StockSEC:0001593968-23-001469:0
2,500 shares@ US$15.771.9% of flowCommon StockSEC:0001593968-23-001365:0
2,500 shares@ US$18.922.2% of flowCommon StockSEC:0001593968-23-001247:0
460 shares@ US$12.000.3% of flowCommon StockSEC:0001593968-23-001141:0
920 shares@ US$12.000.5% of flowCommon StockSEC:0001593968-23-001051:0
25 of 156 declarations
About RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on Nasdaq in the United States. Headquartered in South San Francisco, California, the company was incorporated in March 2015 under the name FLX Bio, Inc. and adopted the RAPT Therapeutics name in May 2019. It is best described as a clinical-stage immunology company focused on discovering, developing, and commercializing therapies for patients with inflammatory and immunologic diseases that still have significant unmet medical need. ([investors.rapt.com](https://investors.rapt.com/?utm_source=openai))
RAPT’s business model is centered on internal drug discovery and clinical development rather than on an established commercial franchise. The company has historically advanced a pipeline that included oncology and immunology assets, such as tivumecirnon (RPT475) and zelnecirnon (RPT193), but its current strategic emphasis is clearly on immunology, especially allergy-related indications. Its lead focus has shifted to RPT904, a long-acting anti-IgE antibody designed for food allergy and other IgE-mediated diseases, including chronic spontaneous urticaria. This makes the company a focused, science-driven development-stage player in a highly competitive specialty biotech segment. ([investors.rapt.com](https://investors.rapt.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, RAPT is not a large diversified pharma company; instead, it competes as a niche clinical-stage innovator. Its potential differentiation lies in immunology expertise, selective mechanisms, and the possibility of delivering more targeted treatments in underserved allergic and inflammatory conditions. That said, the company’s prospects remain heavily dependent on clinical readouts, regulatory progress, and access to capital, which is typical for a pre-revenue or early-revenue biotech company. In other words, the investment case is driven more by pipeline execution than by current commercial scale. ([investors.rapt.com](https://investors.rapt.com/?utm_source=openai))
Geographically, RAPT’s footprint is concentrated in the United States, with its principal executive offices and main operational base in South San Francisco, California, a major biotech hub. The company has also disclosed an Australian subsidiary, but its core development activities remain U.S.-centered. As a Nasdaq-listed issuer, the stock is generally sensitive to clinical updates, FDA milestones, financing events, and insider transaction disclosures, which are especially relevant in the context of SEC Form 4 monitoring. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1673772/000095017025034185/rapt-20241231.htm?utm_source=openai))
Recent milestones are notable. RAPT reported full-year 2024 results in March 2025 and said its 2025 priorities would center on advancing RPT904. In December 2024, the company raised capital through a private placement, improving its financial flexibility for ongoing development work. Most importantly, in September 2025, RAPT announced FDA clearance to proceed with a Phase 2b trial of RPT904 in food allergy, a meaningful clinical step that supports the company’s current strategic pivot toward IgE-mediated diseases. ([investors.rapt.com](https://investors.rapt.com/node/10341/pdf?utm_source=openai))
